152 filings
8-K
ONCSQ
ONCOSEC MEDICAL Inc
22 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
ONCSQ
ONCOSEC MEDICAL Inc
14 Jun 23
Bankruptcy or Receivership
5:20pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
14 Jun 23
Departure of Directors or Certain Officers
4:55pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
2 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
ONCSQ
ONCOSEC MEDICAL Inc
18 May 23
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:35pm
8-K
t753ps
16 May 23
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
8:15am
8-K
eswla ru1t
27 Apr 23
Other Events
8:00am
8-K
ujbqv4zv
11 Apr 23
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:05pm
8-K
4hiuy32nw f61ha7y4h
3 Apr 23
Other Events
7:30am
8-K
x1e84uhwnhz5sk4bj
22 Feb 23
Other Events
8:30am
8-K
7sjz2lok
4 Jan 23
Amendments to Articles of Incorporation or Bylaws
4:10pm
8-K
3iy9rvpgzq
28 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
jg8k7jki
27 Dec 22
Departure of Directors or Certain Officers
5:00pm
8-K
ertun
1 Dec 22
OncoSec Announces Pricing of $3.5 Million Public Offering
4:57pm
8-K
yp6f3kxf5bq
29 Nov 22
Entry into a Material Definitive Agreement
8:00am
8-K
8ap9smsjsbmkl4k02nqa
22 Nov 22
Other Events
5:00pm
8-K
2mbyhwyz8hu30
15 Nov 22
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
5:06pm
8-K
he5zx5ki0mun
14 Nov 22
Other Events
6:10am
8-K
nd2l4q
8 Nov 22
OncoSec Announces Reverse Stock Split
1:15pm
8-K
i9x4ln
17 Oct 22
Departure of Directors or Certain Officers
5:00pm